Forest Snaps Up SNRI, Builds Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Potential successor to Lexapro may be safer than stalled fibromyalgia drug milnacipran.
You may also be interested in...
FDA Clears Forest’s Savella, The First Fibromyalgia-Only Drug
The selective serotonin and norepenephrine reuptake inhibitor will require a MedGuide, and thus a REMS.
FDA Clears Forest’s Savella, The First Fibromyalgia-Only Drug
The selective serotonin and norepenephrine reuptake inhibitor will require a MedGuide, and thus a REMS.
Scrapping Its IPO, Phenomix Teams Up With Forest
The deal funds ongoing clinical development of dutogliptin and provides a cushion in difficult financial times.